These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

311 related articles for article (PubMed ID: 15205876)

  • 1. The NMDA receptor glycine modulatory site: a therapeutic target for improving cognition and reducing negative symptoms in schizophrenia.
    Coyle JT; Tsai G
    Psychopharmacology (Berl); 2004 Jun; 174(1):32-8. PubMed ID: 15205876
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Converging evidence of NMDA receptor hypofunction in the pathophysiology of schizophrenia.
    Coyle JT; Tsai G; Goff D
    Ann N Y Acad Sci; 2003 Nov; 1003():318-27. PubMed ID: 14684455
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Cognitive and Negative Symptoms in Schizophrenia Trial (CONSIST): the efficacy of glutamatergic agents for negative symptoms and cognitive impairments.
    Buchanan RW; Javitt DC; Marder SR; Schooler NR; Gold JM; McMahon RP; Heresco-Levy U; Carpenter WT
    Am J Psychiatry; 2007 Oct; 164(10):1593-602. PubMed ID: 17898352
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Substance use disorders and Schizophrenia: a question of shared glutamatergic mechanisms.
    Coyle JT
    Neurotox Res; 2006 Dec; 10(3-4):221-33. PubMed ID: 17197372
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Glutamate and schizophrenia: beyond the dopamine hypothesis.
    Coyle JT
    Cell Mol Neurobiol; 2006; 26(4-6):365-84. PubMed ID: 16773445
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ionotropic glutamate receptors as therapeutic targets in schizophrenia.
    Coyle JT; Tsai G; Goff DC
    Curr Drug Targets CNS Neurol Disord; 2002 Apr; 1(2):183-9. PubMed ID: 12769626
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The NMDA receptor 'glycine modulatory site' in schizophrenia: D-serine, glycine, and beyond.
    Balu DT; Coyle JT
    Curr Opin Pharmacol; 2015 Feb; 20():109-15. PubMed ID: 25540902
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Meta-analysis of the efficacy of adjunctive NMDA receptor modulators in chronic schizophrenia.
    Singh SP; Singh V
    CNS Drugs; 2011 Oct; 25(10):859-85. PubMed ID: 21936588
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment of negative and cognitive symptoms.
    Javitt DC
    Curr Psychiatry Rep; 1999 Oct; 1(1):25-30. PubMed ID: 11122902
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Placebo-controlled trial of glycine added to clozapine in schizophrenia.
    Evins AE; Fitzgerald SM; Wine L; Rosselli R; Goff DC
    Am J Psychiatry; 2000 May; 157(5):826-8. PubMed ID: 10784481
    [TBL] [Abstract][Full Text] [Related]  

  • 11. D-serine added to clozapine for the treatment of schizophrenia.
    Tsai GE; Yang P; Chung LC; Tsai IC; Tsai CW; Coyle JT
    Am J Psychiatry; 1999 Nov; 156(11):1822-5. PubMed ID: 10553752
    [TBL] [Abstract][Full Text] [Related]  

  • 12. D-cycloserine increases positive symptoms in chronic schizophrenic patients when administered in addition to antipsychotics: a double-blind, parallel, placebo-controlled study.
    van Berckel BN; Evenblij CN; van Loon BJ; Maas MF; van der Geld MA; Wynne HJ; van Ree JM; Kahn RS
    Neuropsychopharmacology; 1999 Aug; 21(2):203-10. PubMed ID: 10432468
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A multicenter, add-on randomized controlled trial of low-dose d-serine for negative and cognitive symptoms of schizophrenia.
    Weiser M; Heresco-Levy U; Davidson M; Javitt DC; Werbeloff N; Gershon AA; Abramovich Y; Amital D; Doron A; Konas S; Levkovitz Y; Liba D; Teitelbaum A; Mashiach M; Zimmerman Y
    J Clin Psychiatry; 2012 Jun; 73(6):e728-34. PubMed ID: 22795211
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Potentiation of the NMDA receptor in the treatment of schizophrenia: focused on the glycine site.
    Shim SS; Hammonds MD; Kee BS
    Eur Arch Psychiatry Clin Neurosci; 2008 Feb; 258(1):16-27. PubMed ID: 17901997
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Glutamatergic mechanisms in schizophrenia.
    Tsai G; Coyle JT
    Annu Rev Pharmacol Toxicol; 2002; 42():165-79. PubMed ID: 11807169
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of glutamate positive modulators on cognitive deficits in schizophrenia: a systematic review and meta-analysis of double-blind randomized controlled trials.
    Iwata Y; Nakajima S; Suzuki T; Keefe RS; Plitman E; Chung JK; Caravaggio F; Mimura M; Graff-Guerrero A; Uchida H
    Mol Psychiatry; 2015 Oct; 20(10):1151-60. PubMed ID: 26077694
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Glutaminergic hypothesis of schizophrenia: clinical research studies with ketamine].
    Mechri A; Saoud M; Khiari G; d'Amato T; Dalery J; Gaha L
    Encephale; 2001; 27(1):53-9. PubMed ID: 11294039
    [TBL] [Abstract][Full Text] [Related]  

  • 18. N-Methyl-D-aspartate receptors as a target for improved antipsychotic agents: novel insights and clinical perspectives.
    Millan MJ
    Psychopharmacology (Berl); 2005 Apr; 179(1):30-53. PubMed ID: 15761697
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparative Pro-cognitive and Neurochemical Profiles of Glycine Modulatory Site Agonists and Glycine Reuptake Inhibitors in the Rat: Potential Relevance to Cognitive Dysfunction and Its Management.
    Fone KCF; Watson DJG; Billiras RI; Sicard DI; Dekeyne A; Rivet JM; Gobert A; Millan MJ
    Mol Neurobiol; 2020 May; 57(5):2144-2166. PubMed ID: 31960362
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Glycine transporter I inhibitor, N-methylglycine (sarcosine), added to clozapine for the treatment of schizophrenia.
    Lane HY; Huang CL; Wu PL; Liu YC; Chang YC; Lin PY; Chen PW; Tsai G
    Biol Psychiatry; 2006 Sep; 60(6):645-9. PubMed ID: 16780811
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.